380 related articles for article (PubMed ID: 31886284)
1. FOXO1 Mediates Advanced Glycation End Products Induced Mouse Osteocyte-Like MLO-Y4 Cell Apoptosis and Dysfunctions.
Zhang C; Wei W; Chi M; Wan Y; Li X; Qi M; Zhou Y
J Diabetes Res; 2019; 2019():6757428. PubMed ID: 31886284
[TBL] [Abstract][Full Text] [Related]
2. Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells.
Tanaka K; Yamaguchi T; Kanazawa I; Sugimoto T
Biochem Biophys Res Commun; 2015 May; 461(2):193-9. PubMed ID: 25721666
[TBL] [Abstract][Full Text] [Related]
3. Advanced Glycation End Product 3 (AGE3) Increases Apoptosis and the Expression of Sclerostin by Stimulating TGF-β Expression and Secretion in Osteocyte-Like MLO-Y4-A2 Cells.
Notsu M; Kanazawa I; Takeno A; Yokomoto-Umakoshi M; Tanaka KI; Yamaguchi T; Sugimoto T
Calcif Tissue Int; 2017 Apr; 100(4):402-411. PubMed ID: 28229177
[TBL] [Abstract][Full Text] [Related]
4. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway.
Wijenayaka AR; Kogawa M; Lim HP; Bonewald LF; Findlay DM; Atkins GJ
PLoS One; 2011; 6(10):e25900. PubMed ID: 21991382
[TBL] [Abstract][Full Text] [Related]
5. Iron overload induced osteocytes apoptosis and led to bone loss in Hepcidin
Ma J; Wang A; Zhang H; Liu B; Geng Y; Xu Y; Zuo G; Jia P
Bone; 2022 Nov; 164():116511. PubMed ID: 35933095
[TBL] [Abstract][Full Text] [Related]
6. Advanced glycation end-product 2 and Porphyromonas gingivalis lipopolysaccharide increase sclerostin expression in mouse osteocyte-like cells.
Sakamoto E; Kido JI; Takagi R; Inagaki Y; Naruishi K; Nagata T; Yumoto H
Bone; 2019 May; 122():22-30. PubMed ID: 30735798
[TBL] [Abstract][Full Text] [Related]
7. IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity In Vitro.
Wu Q; Zhou X; Huang D; Ji Y; Kang F
Cell Physiol Biochem; 2017; 41(4):1360-1369. PubMed ID: 28278513
[TBL] [Abstract][Full Text] [Related]
8. Iron Overload-Induced Osteocyte Apoptosis Stimulates Osteoclast Differentiation Through Increasing Osteocytic RANKL Production In Vitro.
Yang J; Dong D; Luo X; Zhou J; Shang P; Zhang H
Calcif Tissue Int; 2020 Nov; 107(5):499-509. PubMed ID: 32995951
[TBL] [Abstract][Full Text] [Related]
9. Disruption of the Cx43/miR21 pathway leads to osteocyte apoptosis and increased osteoclastogenesis with aging.
Davis HM; Pacheco-Costa R; Atkinson EG; Brun LR; Gortazar AR; Harris J; Hiasa M; Bolarinwa SA; Yoneda T; Ivan M; Bruzzaniti A; Bellido T; Plotkin LI
Aging Cell; 2017 Jun; 16(3):551-563. PubMed ID: 28317237
[TBL] [Abstract][Full Text] [Related]
10. HIF-1α induces hypoxic apoptosis of MLO-Y4 osteocytes via JNK/caspase-3 pathway and the apoptotic-osteocyte-mediated osteoclastogenesis in vitro.
Song X; Tang Y; Zhu J; Tian Y; Song Z; Hu X; Hong C; Cai Y; Kang F
Tissue Cell; 2020 Dec; 67():101402. PubMed ID: 32835935
[TBL] [Abstract][Full Text] [Related]
11. Glucose uptake inhibition decreases expressions of receptor activator of nuclear factor-kappa B ligand (RANKL) and osteocalcin in osteocytic MLO-Y4-A2 cells.
Takeno A; Kanazawa I; Notsu M; Tanaka KI; Sugimoto T
Am J Physiol Endocrinol Metab; 2018 Feb; 314(2):E115-E123. PubMed ID: 29018002
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation end products induced IL-6 and VEGF-A production and apoptosis in osteocyte-like MLO-Y4 cells by activating RAGE and ERK1/2, P38 and STAT3 signalling pathways.
Chen H; Liu W; Wu X; Gou M; Shen J; Wang H
Int Immunopharmacol; 2017 Nov; 52():143-149. PubMed ID: 28910744
[TBL] [Abstract][Full Text] [Related]
13. MLO-Y4 osteocyte-like cells support osteoclast formation and activation.
Zhao S; Zhang YK; Harris S; Ahuja SS; Bonewald LF
J Bone Miner Res; 2002 Nov; 17(11):2068-79. PubMed ID: 12412815
[TBL] [Abstract][Full Text] [Related]
14. Avenanthramides Prevent Osteoblast and Osteocyte Apoptosis and Induce Osteoclast Apoptosis in Vitro in an Nrf2-Independent Manner.
Pellegrini GG; Morales CC; Wallace TC; Plotkin LI; Bellido T
Nutrients; 2016 Jul; 8(7):. PubMed ID: 27409635
[TBL] [Abstract][Full Text] [Related]
15. Sclerostin Promotes Bone Remodeling in the Process of Tooth Movement.
Shu R; Bai D; Sheu T; He Y; Yang X; Xue C; He Y; Zhao M; Han X
PLoS One; 2017; 12(1):e0167312. PubMed ID: 28081119
[TBL] [Abstract][Full Text] [Related]
16. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.
Kogawa M; Wijenayaka AR; Ormsby RT; Thomas GP; Anderson PH; Bonewald LF; Findlay DM; Atkins GJ
J Bone Miner Res; 2013 Dec; 28(12):2436-48. PubMed ID: 23737439
[TBL] [Abstract][Full Text] [Related]
17. Osteocyte TSC1 promotes sclerostin secretion to restrain osteogenesis in mice.
Liu W; Wang Z; Yang J; Wang Y; Li K; Huang B; Yan B; Wang T; Li M; Zou Z; Yang J; Xiao G; Cui ZK; Liu A; Bai X
Open Biol; 2019 May; 9(5):180262. PubMed ID: 31088250
[TBL] [Abstract][Full Text] [Related]
18. Monosodium urate crystals reduce osteocyte viability and indirectly promote a shift in osteocyte function towards a proinflammatory and proresorptive state.
Chhana A; Pool B; Callon KE; Tay ML; Musson D; Naot D; McCarthy G; McGlashan S; Cornish J; Dalbeth N
Arthritis Res Ther; 2018 Sep; 20(1):208. PubMed ID: 30201038
[TBL] [Abstract][Full Text] [Related]
19. Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis.
Kim HJ; Kim HJ; Choi Y; Bae MK; Hwang DS; Shin SH; Lee JY
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30909508
[TBL] [Abstract][Full Text] [Related]
20. Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes.
Allison H; Holdsworth G; McNamara LM
BMC Mol Cell Biol; 2020 Nov; 21(1):78. PubMed ID: 33148174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]